Form 8-K - Current report:
SEC Accession No. 0001193125-21-244642
Filing Date
2021-08-12
Accepted
2021-08-12 16:01:04
Documents
14
Period of Report
2021-08-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d166164d8k.htm   iXBRL 8-K 28075
2 EX-99.1 d166164dex991.htm EX-99.1 10427
6 GRAPHIC g166164g52u08.jpg GRAPHIC 4808
  Complete submission text file 0001193125-21-244642.txt   177211

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tars-20210810.xsd EX-101.SCH 2880
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tars-20210810_lab.xml EX-101.LAB 18888
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tars-20210810_pre.xml EX-101.PRE 11852
7 EXTRACTED XBRL INSTANCE DOCUMENT d166164d8k_htm.xml XML 3483
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 211167369
SIC: 2836 Biological Products, (No Diagnostic Substances)